OncLive TV

Amy W. Zhou, MD, discusses the investigation of ruxolitinib given in conjunction with novel or emerging agents such as pacritinib and momelotinib, highlighting these agents’ potential at contributing to the treatment paradigm in myelofibrosis.

Vitaly Margulis, MD, discusses significant factors and comorbidities that may affect treatment decisions for patients with renal cell carcinoma.

Renee Kurz, DNP, FNP-BC, AOCNP, discusses social determinants of health that can contribute to disparities in cancer care, highlighting examples seen throughout New Jersey that emphasize the need for further investigation into this landscape.

J. Nicholas Bodor, MD, PhD, MPH, discusses the results of prior research supporting the inception of a study that profiled reactive estrogen species in women with EGFR-positive non–small cell lung cancer, as well as the findings from this study.

Jacqueline Aredo, MD, MS, discusses findings from a study assessing the molecular distribution of driver mutations and tumor suppressor gene mutations in patients with non–small cell lung cancer who are eligible for lung cancer screening.

Meral Beksac, MD, discusses overall survival data from the phase 3 OPTIMISMM trial in relapsed/refractory multiple myeloma.

Wesley J. Talcott, MD, MBA, discusses the importance of de-escalating therapy in patients with breast cancer, highlighting use of personalized treatment approaches.

Tiago Biachi, MD, PhD, discusses the growing treatment landscape for patients with hepatocellular carcinoma.

S. Alex Mastroyannis, MD, MSCE, discusses the administration and role of hyperthermic intraperitoneal chemotherapy in ovarian cancer, as well as its benefit for patients in the phase 3 OVHIPEC-1 trial.

Kevin Kayvan Zarrabi, MD, MS, FACP, discusses remaining questions regarding treatment consisting of triplet therapy in patients with metastatic castration-sensitive prostate cancer.

Arutha Kulasinghe, PhD, discusses findings from a study profiling the tumor microenvironment of non–small cell lung cancer, as well as future directions planned with this research and the implications of these findings.

Andrea Billè, MD, discusses findings from a propensity-matched comparison of minimally invasive surgery vs stereotactic ablative radiotherapy in patients with clinical stage I non–small cell lung cancer.

Tian Zhang, MD, MHS, discusses the selection of first-line immunotherapy-based treatments for patients with metastatic renal cell carcinoma.

Anand Narayan, MD, PhD, discusses how outcomes differ between different subgroups of patients who are diagnosed with breast cancer, highlighting how these differences tie back to disparities in cancer care.

J. Randolph (Randy) Hecht, MD, discusses barriers to enrollment in the observational BASECAMP-1 study and the phase 1/2 EVEREST-1 study, which will investigate HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in patients with solid tumors.

Qian (Janie) Qin, MD, discusses the investigation and use of CAR T-cell therapy in patients with advanced clear cell renal cell carcinoma.

Vitaly Margulis, MD, discusses key disease characteristics and patient factors to consider when selecting between IO/IO vs IO/TKI treatment combinations for the management of patients with renal cell carcinoma.

Mary “Nora” Disis, MD, discusses the rationale for investigating the efficacy and optimal delivery of PRGN-3005 autologous UltraCAR T cells in patients with advanced stage platinum-resistant ovarian cancer.

J. Randolph (Randy) Hecht, MD, discusses the observational BASECAMP-1 study and the investigation of HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in the phase 1/2 EVEREST-1 study, which will investigate A2B530 in patients with solid tumors.

Qian (Janie) Qin, MD, discusses emerging treatment regimens for patients with advanced clear cell renal cell carcinoma.

Ajai Chari, MD, director, discusses the safety profile of talquetamab following the drug’s FDA approval for patients with relapsed/refractory multiple myeloma.

Jonathan W. Riess, MD, MS, discusses preliminary results from a phase 2 trial of the IO102-IO103 immuno-modulating cancer vaccine plus pembrolizumab in patients with metastatic non–small cell lung cancer adenocarcinoma.

Joachim G. J. V. Aerts, MD, PhD, discusses findings from the phase 3 DENIM trial in patients with mesothelioma, which was presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.

Key opinion leaders from across the hematologic oncology realm shared their biggest takeaways from the 2023 SOHO Annual Meeting.

Naval G. Daver, MD, discusses the rationale for an ongoing phase 1 trial investigating uproleselan in combination with azacitidine and venetoclax in patients with treatment-naïve acute myeloid leukemia.

Pasi A. Jänne, MD, PhD, discusses key findings from the primary analysis of the phase 2 DESTINY-Lung02 trial in patients with HER2-mutant non–small cell lung cancer.

Bhavana Pothuri, MD, discusses the use of antibody-drug conjugates in patients with ovarian cancer and AEs to be aware of when treating patients with these therapies.

Saad Z. Usmani, MD, MBA, FACP, discusses unmet needs in patients with high-risk multiple myeloma being treated in the frontline setting, highlighting areas of potential further exploration within this landscape.

J. Randolph (Randy) Hecht, MD, discusses barriers to treatment with CAR T-cell therapy in patients with solid tumors, highlighting various efforts that investigators are spearheading to address these unmet needs.

Alessandro Di Federico, MD, discusses findings from a study investigating the correlation between TTF-1 expression and outcomes with immunotherapy-based treatments in patients with lung adenocarcinoma.